Avidity Biosciences, Inc.

Avidity Biosciences is a biopharmaceutical company developing antibody oligonucleotide conjugates (AOCs), a proprietary platform designed to deliver RNA therapeutics to specific cell types. The AOC approach combines monoclonal antibody targeting with RNA-based therapeutics to address diseases previously inaccessible to similar treatments. The company focuses on rare genetic and neuromuscular disorders where tissue-specific delivery is clinically important.

The clinical pipeline includes three programs advancing through development stages. Delpacibart zotadirsen is being studied in an open-label extension for Duchenne muscular dystrophy, delpacibart etedesiran is in Phase 3 development for myotonic dystrophy type 1, and delpacibart braxlosiran is in Phase 1/2 studies for facioscapulohumeral muscular dystrophy. The company is also pursuing precision cardiology candidates targeting rare genetic cardiomyopathies, including programs for phospholamban cardiomyopathy and PRKAG2-related syndrome.

The company operates with approximately 511 full-time employees and is headquartered in San Diego, California. As of February 2026, Avidity Biosciences operates as a subsidiary of Novartis AG, following its acquisition by the multinational pharmaceutical company.